Abbott Laboratories number of employees

Abbott Laboratories reported 115,000 employees at December 31, 2025 in its latest annual report, up 1,000 (0.9%) on the year before. That compares with 113,000 at December 31, 2021. Revenue per employee was $385,461.

Headcount by year

Fiscal year end	Employees	Change	Revenue per employee	Source
December 31, 2025	115,000	+1,000 (0.9%)	$385,461	10-K, filed February 20, 2026
December 31, 2024	114,000	+0 (0.0%)	$367,982	10-K, filed February 21, 2025
December 31, 2023	114,000	−1,000 (0.9%)	$351,833	10-K, filed February 16, 2024
December 31, 2022	115,000	+2,000 (1.8%)	$379,591	10-K, filed February 17, 2023
December 31, 2021	113,000	—	$381,195	10-K, filed February 18, 2022

What the annual reports say

As of December 31, 2025, Abbott employed approximately 115,000 people, 69% of whom were employed outside of the U.S. 2025 annual report
As of December 31, 2024, Abbott employed approximately 114,000 people, 69% of whom were employed outside of the U.S. 2024 annual report
As of December 31, 2023, Abbott employed approximately 114,000 people, 69% of whom were employed outside of the U.S. 2023 annual report
As of December 31, 2022, Abbott employed approximately 115,000 people, 69% of whom were employed outside of the U.S. 2022 annual report
As of December 31, 2021, Abbott employed approximately 113,000 people, 70% of whom were employed outside of the U.S. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: ABT vs MDT ABT vs SYK ABT vs GEHC

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Abbott Laboratories's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abbott Laboratories.